Mind Medicine has altered its state, rebranding as Definium Therapeutics ahead of a series of phase 3 data drops on its lead ...

Listening to patients is no longer a “nice to have” for life sciences companies—it is a strategic necessity that can ...

Five months ago, J&J also revealed its plan to spend $2 billion over the next 10 years to operate a 160,000-square-foot ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Early launch numbers of Brinsupri are so strong that Insmed couldn’t wait for the J.P. Morgan Healthcare Conference to share ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house ...

Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill, Nereus. The decision came 15 months after the ...

In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...